Hunter, Rose Published in Intellectual Property Magazine About Overcoming Challenges to Patent Eligibility

July/August 2020 Intellectual Property Magazine News
Partner Paul Hunter and Senior Counsel Daniel Rose were published in Intellectual Property Magazine. Their article, “Moving Target,” discussed approaches to overcoming challenges to patent eligibility in light of recent jurisprudence and inconsistent policy. 

“Patent eligibility defines what can be patented. Over the past decade, the standard for such eligibility in the US  has been a moving target with courts and the US Patent and Trademark Office (USPTO) lacking a consistent voice. Only recently have jurisprudence and the USPTO found similar approaches to assessing eligibility,” they wrote. 

“After four decisions on patent subject matter eligibility in the early 2010s – Bilski, Mayo, Myriad, and Alice – the Supreme Court of the US has sat on the sidelines and let the Federal Circuit and the USPTO hash out the details of this developing area of law. The Justices have declined to hear any eligibility questions this term, even rejecting an appeal from the Federal Circuit’s en banc denial for rehearing in Athena v Mayo this past summer that resulted in nine separate opinions. Lower courts and the USPTO have struggled with confusing and inconsistent precedent, resulting in a lack of clarity and predictability.”

Read the full article here.

(Subscription required)

Related Services


Review of Recent Whistleblower Developments
30 July 2021
Legal News: Whistleblower Developments
$4.24M Now the Average Cost Per Data Breach!
30 July 2021
Internet, IT & e-Discovery Blog
Podcast Episode 56: All Things Summer Associate Recruiting
30 July 2021
Foley Career Perspectives
Foley Podcast to Live Panel Discussion
29 July 2021
Foley Career Perspectives
30th Annual Law of Product Distribution & Franchise Seminar
29 September | 7 & 20 October 2021
Milwaukee | Chicago | Dallas
7th National Telehealth Summit
4-5 October 2021
Miami Beach, FL
AHLA Fraud & Compliance Forum
21-22 September 2021
Baltimore, MD
2nd Clinical Trial Agreements Forum
16-17 September 2021
Online Livestream